Holen Sie sich die Stockscreener-App
3.46
0.72%
-0.03
Schlusskurs vom Vortag:
$3.49
Offen:
$3.51
24-Stunden-Volumen:
321.51K
Relative Volume:
0.82
Marktkapitalisierung:
$274.58M
Einnahmen:
$351.37M
Nettoeinkommen (Verlust:
$-174.01M
KGV:
-1.6715
EPS:
-2.07
Netto-Cashflow:
$-126.94M
1W Leistung:
+2.51%
1M Leistung:
-2.94%
6M Leistung:
+10.00%
1J Leistung:
-7.35%
1-Tages-Spanne:
$3.41
$3.535
1-Wochen-Bereich:
$3.33
$3.60
52-Wochen-Spanne:
$2.455
$4.145
Atea Pharmaceuticals Inc Stock (AVIR) Company Profile
Firmenname
Atea Pharmaceuticals Inc
Sektor
Branche
Telefon
857-204-8109
Adresse
225 FRANKLIN STREET, BOSTON
Vergleichen Sie AVIR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
AVIR
Atea Pharmaceuticals Inc
|
3.46 | 277.75M | 351.37M | -174.01M | -126.94M | -2.07 |
|
VRTX
Vertex Pharmaceuticals Inc
|
392.06 | 101.51B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
578.37 | 59.52B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
448.07 | 56.69B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
652.39 | 39.57B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
319.54 | 36.56B | 3.81B | -644.79M | -669.77M | -6.24 |
Atea Pharmaceuticals Inc Stock (AVIR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-13 | Hochstufung | Morgan Stanley | Underweight → Equal-Weight |
| 2023-08-10 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2022-01-06 | Herabstufung | Morgan Stanley | Equal-Weight → Underweight |
| 2021-11-18 | Herabstufung | SVB Leerink | Outperform → Mkt Perform |
| 2021-10-20 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-10-05 | Herabstufung | Morgan Stanley | Overweight → Equal-Weight |
| 2020-11-25 | Eingeleitet | Evercore ISI | Outperform |
| 2020-11-24 | Eingeleitet | JP Morgan | Overweight |
| 2020-11-24 | Eingeleitet | Morgan Stanley | Overweight |
| 2020-11-24 | Eingeleitet | William Blair | Outperform |
Alle ansehen
Atea Pharmaceuticals Inc Aktie (AVIR) Neueste Nachrichten
Atea Pharmaceuticals’ Earnings Call Highlights HCV Progress - MSN
What Fibonacci levels say about Atea Pharmaceuticals Inc. rebound2025 Price Momentum & Breakout Confirmation Alerts - Newser
What the charts say about Atea Pharmaceuticals Inc. todayJuly 2025 Sector Moves & Low Risk High Win Rate Stock Picks - Newser
Published on: 2025-08-15 03:01:02 - Newser
Quantitative breakdown of Atea Pharmaceuticals Inc. recent moveWeekly Trade Analysis & Low Risk High Reward Trade Ideas - Newser
Signal strength of Atea Pharmaceuticals Inc. stock in tech scanners2025 Market Outlook & Daily Technical Stock Forecast Reports - Newser
Volatility clustering patterns for Atea Pharmaceuticals Inc.July 2025 Opening Moves & Consistent Profit Trade Alerts - Newser
Atea Pharmaceuticals Inc. stock daily chart insightsJuly 2025 Fed Impact & Safe Swing Trade Setup Alerts - Newser
What earnings revisions data tells us about Atea Pharmaceuticals Inc.July 2025 EndofMonth & Trade Opportunity Analysis Reports - Newser
Developing predictive dashboards with Atea Pharmaceuticals Inc. dataQuarterly Portfolio Review & Daily Momentum Trading Reports - Newser
Is Atea Pharmaceuticals Inc. trending in predictive chart modelsTrade Signal Summary & Fast Exit and Entry Trade Guides - Newser
Analyzing net buyer seller activity in Atea Pharmaceuticals Inc.Trade Analysis Summary & Safe Entry Trade Reports - Newser
Is Atea Pharmaceuticals Inc. meeting your algorithmic filter criteria2025 Breakouts & Breakdowns & Fast Entry and Exit Trade Plans - Newser
Will Atea Pharmaceuticals Inc. price bounce be sustainable2025 Retail Activity & Risk Controlled Daily Trade Plans - Newser
Published on: 2025-08-13 07:15:38 - Newser
Atea Pharmaceuticals Inc. stock momentum explainedEarnings Summary Report & Weekly Stock Performance Updates - Newser
Regression analysis insights on Atea Pharmaceuticals Inc. performance [Earnings Risk Summary]Free Short-Term High Return Strategies - Newser
Detecting support and resistance levels for Atea Pharmaceuticals Inc. [Profit Target]Stock Market Timing Techniques - Newser
Why Atea Pharmaceuticals Inc. stock attracts strong analyst attentionFree Alpha Driven Watchlist With Alerts - Newser
Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Q2 2025 Earnings Call Transcript - Insider Monkey
How institutional ownership impacts Atea Pharmaceuticals Inc. stockMulti-Year Signal Summary and Entry Timing - Newser
What candlestick patterns are forming on Atea Pharmaceuticals Inc.Trend Following Ideas with Volume Confirmation - Newser
How to build a custom watchlist for Atea Pharmaceuticals Inc.Free Swing Setup With Technical Confirmation - Newser
Atea Pharmaceuticals Inc. stock outlook for YEARFree High Accuracy Alerts for ROI Traders - Newser
Institutional scanner results for Atea Pharmaceuticals Inc.AI-Based Reversal Point Prediction Signal - Newser
Does Atea Pharmaceuticals Inc. fit your quant trading modelFree Triple Return Setup with Risk Control - Newser
Using data tools to time your Atea Pharmaceuticals Inc. exitFree Swing Setup With Technical Confirmation - Newser
Visualizing Atea Pharmaceuticals Inc. stock with heatmapsBreakout Watcher with Entry and Exit Alerts - Newser
Is Atea Pharmaceuticals Inc. forming a bottoming baseAI Trading Forecast Based on Big Data - Newser
Atea Pharmaceuticals (AVIR): A High-Growth HCV Play with Clinical and Financial Momentum - AInvest
Atea Pharmaceuticals (NASDAQ:AVIR) Stock Rating Lowered by Wall Street Zen - Defense World
William Blair Keeps Their Buy Rating on Atea Pharmaceuticals (AVIR) - The Globe and Mail
Finanzdaten der Atea Pharmaceuticals Inc-Aktie (AVIR)
Umsatz
Nettogewinn
Free Cashflow
ENV
Atea Pharmaceuticals Inc-Aktie (AVIR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| BERGER FRANKLIN M | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
506,497 |
| Duncan Barbara Gayle | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Polsky Bruce | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
95,206 |
| Adams Jerome M. | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
62,750 |
| Lucidi Bruno | Director |
Jun 20 '25 |
Option Exercise |
0.00 |
29,600 |
0 |
112,750 |
| BERGER FRANKLIN M | Director |
Dec 10 '24 |
Sale |
2.85 |
359,606 |
1,023,475 |
451,897 |
0.06%
0.58%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):